Blood test could track muscle disease progress in real time, study finds
Researchers identified a panel of serum proteins that accurately reflect how quickly children with Duchenne muscular dystrophy lose muscle function. The discovery could transform clinical trials and treatment monitoring by replacing time-consuming physical tests with simple blood draws—potentially accelerating drug development for this fatal genetic disorder.
Originaltitel: Evaluation of a serum protein signature as monitoring biomarker for Duchenne muscular dystrophy in a long-term clinical trial with corticosteroids.
En serum-proteinpanel kan förbättra övervakningen av Duchenne-muskeldystrofi (DMD) och ersätta eller komplettera traditionella funktionsmätningar i kliniska prövningar. Forskare från Leiden University och samarbetspartner analyserade blodprover från DMD-patienter i en korticosteroid-studie genom aptamer-baserad proteomik (SomaScan), profilerade cirka 1500 proteiner och identifierade fyra nyckelprokein: RGMA, ART3, ANTXR2 och CFB. Prediktionsmodeller som inkluderade dessa proteiner förbättrade noggrannheten med 12 procent för NSAA-test och 33–35 procent för RFV och 10MRWV. De valda proteinerna uppvisade stark överensstämmelse mellan olika analysmetoder. För biopharmabolag som utvecklar DMD-terapier innebär detta ett möjligt instrument för snabbare och objektivare uppföljning av effekt, vilket kan förkorta utvecklingstid och förbättra trial-design. Praktisk implementering kräver validering i ytterligare kohort innan rutinövervakning.
BACKGROUND: Duchenne muscular dystrophy (DMD) is a progressive neuromuscular disorder for which monitoring biomarkers are urgently needed. We aimed to evaluate whether proteins in serum can accurately monitor patients' function within the duration of a clinical trial. METHODS: In this study, we evaluated longitudinal serum proteins of DMD patients participating in the FOR-DMD clinical trial, comparing daily and intermittent corticosteroid regimens in boys aged 4-8 years at baseline. Using the aptamer-based protein platform SomaScan, we profiled 1500 proteins. Associations between protein levels and motor function outcomes, such as Rise from the Floor Velocity (RFV), 10-Meter Run/Walk Velocity (10MRWV), and North Star Ambulatory Assessment (NSAA), were assessed using linear mixed models. In particular, we explored whether patients with higher protein levels also tended to have better functional scores (across-patients analysis), and whether changes in protein levels within the same patient over time were linked to changes in their functional performance (within-patient analysis). Finally, penalized (lasso) mixed models were applied to evaluate the predictive function of the proteins. The prediction accuracy of the models (evaluated by optimism-corrected Root Mean Squared Error) was compared to that of a simpler model with only age and treatment as predictors. RESULTS: Across-patients and within-patient analyses revealed consistent associations with three functional tests for a subset of proteins, notably RGMA, ART3, ANTXR2, and CFB. Multivariate models incorporating the proteins significantly associated with at least two tests, improved prediction accuracy by 12% for NSAA, and by 33-35% for RFV and 10MRWV. These models also revealed a subset of proteins that were consistently selected. Quantification of CFB, RGMA, ANTXR2, SERPINF1 and ATP5PF using SomaScan showed strong agreement with measurements obtained using orthogonal methods such as ELISA, MRM-MS and an in-house developed bead-based sandwich immunoassay. CONCLUSIONS: These findings support the utility of serum protein signatures as objective, quantitative tools for monitoring disease progression and treatment response in DMD during clinical visits and clinical trials. TRIAL REGISTRATION: The FOR-DMD clinical trial was registered at ClinicalTrials.gov (registration no. NCT01603407). First submission: 03/04/2012.